Dendritic Cell and Tumor Cell Cancer Vaccines Market Size, Share, Growth 2019, Analysis by Antigen, Application, End-Users, Regional Segmentation and Key Player Profiles upto 2027
Global Dendritic Cell and Tumor Cell Vaccines Market
Cancer is caused due to an abnormal growth of cells in the body, which is also known as malignancy. This disease is capable of rapidly replicating itself and invading into other body parts. Dendritic cells (part of the neurons) play an essential role in inducing anti-tumor activity in the body. Hence, various strategies are being developed to treat cancer with the help of dendritic cells. Thus, for the generation of dendritic vaccines, dendritic cells are cultured alongside the cancer cells. The vaccine, when introduced into the body, stimulates the immune system to attack the cancer cells.
Get Sample PDF (Including COVID-19 Impact Analysis, Full TOC, Tables, and Figures) of Dendritic Cell and Tumor Cell Cancer Vaccines, https://www.coherentmarketinsights.com/insight/request-pdf/2753
Global Dendritic Cell and Tumor Cell Vaccines Market Drivers
Increasing R&D activities associated with dendritic cell and tumor cell-based vaccines are expected to accelerate the global dendritic cell and tumor cell vaccines market growth. For instance, in March 2015, Rockefeller University and Memorial Sloan Kettering Cancer Center conducted a phase II study of autologous dendritic cell vaccines (DC/PC3). It is being used as an immunotherapy in the prostate cancer. The vaccine was developed by patient’s own cells.
Furthermore, in April 2016, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) S.r.l., commenced its study based on autologous dendritic cells loaded with autologous tumor homogenate, in combination with the drug IL-2. This combination was being studied for the treatment of patients with stage IV colorectal cancer. The goal of the study was to evaluate the consistency of the response of immune cells following the completion of the treatment. Currently, the study is in its second phase of clinical trials. Hence, such research and development activities of dendritic cell and tumor cell vaccines are expected to impel the global dendritic cell and tumor cell vaccines market growth.
Furthermore, regulatory approvals of vaccines by regulatory bodies are expected to drive the global dendritic cell and tumor cell vaccines market growth. For instance, in June 2018, Northwest BioTherapeutics received the U.S. Food & Drug Administration (FDA) approval for its dendritic cell vaccine, DCVax – L. It is being used for the treatment of cancer type, glioblastoma. Its clinical study revealed that many patients survived for over one and half years after the vaccination. Hence, such approved vaccines based on dendritic cell are expected to drive the global dendritic cell and tumor cell vaccines market growth.
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2753
Global Dendritic Cell and Tumor Cell Vaccines Market – Regional Analysis
North America is expected to emerge as the most dominant region in the global dendritic cell and tumor cell vaccines market, with the escalating prevalence of cancer in the region. According to the National Institutes of Health (NIH) data, in 2018, around 609,640 people died due to cancer and incidence rate was 439.2 per 100,000 men and women per year. The most occurring cancer type are breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, and kidney and renal pelvis cancer. Hence, the higher prevalence of cancer may lead to higher demand for dendritic cell and tumor cell vaccines and thereby, expected to propel the global dendritic cell and tumor cell vaccines market growth.
Global Dendritic Cell and Tumor Cell Vaccines Market Restraints
Withdrawal of dendritic cell and tumor cell vaccines from the clinical trials is expected to hamper the global dendritic cell and tumor cell vaccines market development. For instance, in March 2016, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, conducted its clinical trial for dendritic cell vaccine with radiotherapy. It was being studied for the treatment of renal cancer. However, it got withdrawn in its second phase of clinical trial (reason unspecified).
Global Dendritic Cell and Tumor Cell Vaccines Market – Key Competitors
Some of the major players operating in the global dendritic cell and tumor cell vaccines market include JW CreaGene, Miltenyi Biotec, GlaxoSmithKline Plc, NorthWest BioTherapeutics, ImmunoCellular Therapeutics, Ltd., EnoChian Biosciences, Medigene AG, DC Prime, Tella Incorporation, and CiMaas.
By Antigen Type,
- CD 4
- CD 8
- T-helper cell
- Glioblastoma Cancer
- Prostate Cancer
- Pancreatic Cancer
- Colorectal Cancer
- Renal Cancer
- Lung Cancer
By Distribution Channel,
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- North America
- Latin America
- Asia Pacific
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire